Vendor Intelligence Report: Haikou Mingheng Biotechnology

Published 3 Jul 2026. 22-page investigative report on who is behind Haikou Mingheng Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 26 Finnrick lab tests, Haikou Mingheng Biotechnology posts 19 pass / 7 fail, an overall pass rate of 73%. The record is uneven rather than catastrophic: tirzepatide is the most defensible tested line, retatrutide is conditional, and cagrilintide is the clearest reason to shop for a better-testing source. Stricter grading also pulls the read downward, so this is a batch-confirmation story, not a brand-trust story.

The non-lab record points to a Haikou-based trader network, not a verified peptide-synthesis facility. Echemi and Xchemi storefronts classify the operation as a Trader, a shared Jixin Plaza shop address ties together Biotechnology and Technology channels, and a third Mingheng account broadens the peptide catalog. Storefront fields and registry-adjacent records also leave a longer operating-history claim unresolved.

Channel authentication is the practical problem. The primary Biotechnology storefront was blocked by human verification in the July 2026 capture while sibling storefronts remained visible; xtmingheng.com functions as an email-branding domain, not a canonical public website. A retatrutide COA adds a document-control warning: the named Liuyang manufacturer address carries a province mismatch, and reviewed field samples lacked batch IDs.

Inside the full report:

  • Per-product Finnrick analysis, methodology-divergence chart, trajectory view, and Appendix A specimen data for all 3 tested products
  • Storefront/account map across Echemi, Xchemi, the sibling Technology shop, and the third Mingheng account
  • Corporate timeline using the Technology USCC record, Qi Shuangshuang registry trail, and Jixin Plaza address evidence
  • xtmingheng.com RDAP, DNS/mail-routing, and named contact infrastructure review for Ms. jia, Mandy, Emily, Annie, and Berry
  • Manufacturing-claim assessment covering the Retatrutide COA location mismatch and weak batch traceability
  • Community and source-coverage notes, including the GLP-1 Forum dataset lead, Reddit broker discussion, and registry access dead ends

Risk assessment

  • Tested-product dosing variability risk — high: Finnrick records 26 tests (19 pass / 7 fail) across Tirzepatide 79.63%, Retatrutide 74.52%, and Cagrilintide 62.3%; Cagrilintide is the weakest tested line and all three require batch-specific confirmation.
  • Batch traceability and recall risk — high: Field notes reported no batch IDs on reviewed Mingheng samples and generic/White Label vial presentation, limiting recall, vial-to-COA matching, and safe re-order decisions.
  • Brokered-supply-chain and manufacturing-claims risk — medium: Echemi/Xchemi classify Mingheng as a Trader at a Haikou shopping-plaza address; the Retatrutide COA points to a separate Liuyang manufacturer address with a Hubei/Hunan mismatch.
  • Channel-authenticity and brand-control risk — medium: Biotechnology, Technology, a third Haikou Mingheng Echemi account, and X posts using Pharmaceutical create name drift; xtmingheng.com is email-only and no canonical official channel list was found.